Abstract:The DNA repair protein PARP-1 emerged as a valuable target in the treatment of tumor entities with deficiencies of BRCA1/2, such as breast cancer. More recently, the application of PARP inhibitors (PARPi) such as olaparib has been expanded to other cancer entities including colorectal cancer (CRC). We previously demonstrated that PARP-1 is overexpressed in human CRC and promotes CRC progression in a mouse model. However, acquired resistance to PARPi and cytotoxicity-mediated adverse effects limit their clinical applicability. Here, we detailed the role of PARP-1 as a therapeutic target in CRC and studied the efficacy of novel PARPi compounds in wildtype (WT) and DNA repair-deficient CRC cell lines together with the chemotherapeutics irinotecan (IT), 5-fluorouracil (5-FU), and oxaliplatin (OXA). Based on the ComPlat molecule archive, we identified novel PARPi candidates by molecular docking experiments in silico, which were then confirmed by in vitro PARP activity measurements. Two promising candidates (X17613 and X17618) also showed potent PARP-1 inhibition in a CRC cell-based assay. In contrast to olaparib, the PARPi candidates caused no PARP-1 trapping and, consistently, were not or only weakly cytotoxic in WT CRC cells and their BRCA2- or ATR-deficient counterparts. Importantly, both PARPi candidates did not affect the viability of nonmalignant human colonic epithelial cells. While both olaparib and veliparib increased the sensitivity of WT CRC cells towards IT, no synergism was observed for X17613 and X17618. Finally, we provided evidence that all PARPi (olaparib > veliparib > X17613 > X17618) synergize with chemotherapeutic drugs (IT > OXA) in a BRCA2-dependent manner in CRC cells, whereas ATR deficiency had only a minor impact. Collectively, our study identified novel lead structures with potent PARP-1 inhibitory activity in CRC cells but low cytotoxicity due to the lack of PARP-1 trapping, which synergized with IT in homologous recombination deficiency.

XRCC2 Promotes Colorectal Cancer Cell Growth, Regulates Cell Cycle Progression, and Apoptosis

Combined Olaparib and Oxaliplatin Inhibits Tumor Proliferation by Cell Cycle Arrest and Cell Apoptosis in XRCC2-defecient Colorectal Cancer

XRCC2 Rs3218536 Polymorphism Decreases the Sensitivity of Colorectal Cancer Cells to Poly(adp-Ribose) Polymerase 1 Inhibitor

Combined Olaparib and Oxaliplatin Inhibits Tumor Proliferation and Induces G(2)/M Arrest and Gamma-H2ax Foci Formation in Colorectal Cancer

Xrcc2 As A Predictive Biomarker for Radioresistance in Locally Advanced Rectal Cancer Patients Undergoing Preoperative Radiotherapy

Overexpression of Xeroderma Pigmentosum Group C Decreases the Chemotherapeutic Sensitivity of Colorectal Carcinoma Cells to Cisplatin

PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.

Protease-activated receptor 2 stabilizes Bcl-xL and regulates EGFR–targeted therapy response in colorectal cancer

Molecular Basis of XRN2-Deficient Cancer Cell Sensitivity to Poly(ADP-ribose) Polymerase Inhibition

PARP in Colorectal Cancer: Molecular Mechanisms, Immunity, Clinical Trials, and Drug Combinations.

XRRA1 Targets ATM/CHK1/2-Mediated DNA Repair in Colorectal Cancer.

XRCC1 mediates PARP1- and PAR-dependent recruitment of PARP2 to DNA damage sites

shRNA-mediated XRCC2 gene knockdown efficiently sensitizes colon tumor cells to X-ray irradiation in vitro and in vivo.

XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA

Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP Inhibitors

Skp2 Stabilizes Mcl-1 and Confers Radioresistance in Colorectal Cancer

PARP5B is required for nonhomologous end joining during tumorigenesis in vivo

Cyclin D1 Silencing Impairs DNA Double Strand Break Repair, Sensitizes BRCA1 Wildtype Ovarian Cancer Cells to Olaparib.

XRCC2 knockdown effectively sensitizes esophageal cancer to albumin-paclitaxel in vitro and in vivo

XRCC 1 Rs 1799782 ( C 194 T ) Polymorphism Correlated with Tumor Metastasis and Molecular Subtypes in Breast Cancer

ASXL2 promotes colorectal cancer tumorigenesis by inducing cell proliferation